Zevalin For Previously Untreated NH Lymphoma

FDA Approves Zevalin® Expanded Label as Part of First-Line Therapy in Treatment of Follicular Non-Hodgkin's Lymphoma

Label Expands Treatable Population To Approximately 43,000 Patients Annually

IRVINE, California – September 4, 2009 –Spectrum Pharmaceuticals (NasdaqGM: SPPI), a commercial-stage biotechnology company with a focus in oncology, today announced ZEVALIN® (ibritumomab tiuxetan), a CD20-directed radiotherapeutic antibody, received approval from the U.S. Food and Drug Administration (FDA) for an expanded label for the treatment of patients with previously untreated follicular non-Hodgkin's Lymphoma (NHL), who achieve a partial or complete response to first-line chemotherapy. This new and expanded indication supplements the 2002 FDA approval of ZEVALIN as treatment for patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma.

http://www.urmc.rochester.edu/news/story/index.cfm?id=2403

http://www.urmc.rochester.edu/news/story/index.cfm?id=2403

Doctors choose a variety of treatments for follicular lymphoma the second most prevalent type of lymphoma.

Stop washing raw chicken, food agency advises - Healthzone.ca

Stop washing raw chicken, food agency advises - Healthzone.ca

Exploiting A Weakness In Cancer's Defense System

Exploiting A Weakness In Cancer's Defense System

The more we find out about the human body the more we don't know!